Advances in the treatment of metastatic colorectal cancer (mCRC) with targeted therapies, including anti-EGFR (e.g., cetuximab) and anti-VEGF (e.g., bevacizumab) therapy in combination with chemotherapy, have improved the outcome for CRC patients1. This evidence concerns the gene EGFR and colorectal carcinoma.